OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium
Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data [...]
The Value of Evaluating Circulating Tumor Cells – Better Survival Predictions
The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, [...]
Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC® Prostate Cancer Immunotherapy
Bavarian Nordic A/S (BAVA) announced on November 15, that its subsidiary, BN ImmunoTherapeutics has started the pivotal Phase 3 trial of PROSTVAC® for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial [...]
Estrogen May Play Role in Melanoma Recurrence- A Warning for Those of Us Who Are Considering Estrogen as a Second Line ADT
According to a an article published in the January 2012 issue of Cancer Prevention Research, estrogen may play a role in Melanoma recurrences! The article described a large cohort study of women who were put [...]
Fighting Infections while on Chemotherapy – Using Neulasta
Neulasta (Pegfilgrastim) is used to reduce the chance of infection in people who have certain cancers and are also receiving chemotherapy medications, including taxotere for men being treated for advanced prostate cancer. Chemotherapy is designed [...]
Data From Phase 3 AFFIRM Trial of MDV3100 in Advanced Prostate Cancer
We are about to finally get a more formal presentation of the great news we have all been waiting to hear. Medivation Inc. and Astellas Pharma Inc. announced that data from their Phase 3 AFFIRM [...]